SWEDEN, 6th December, 2021 - Omnio AB is developing new drug products based on the pro-inflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5MSEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to now initiate its planned activities to develop recombinant plasminogen for treatment of diabetic foot ulcers.
Omnio AB receives patent for use of inhibitors of plasminogen for treating, reducing or preventing radiation-induced injuries
Research group at Umeå University publishes paper on the regulation of wound healing by the plasminogen receptor, Plg-RKT
Omnio AB receives support from SweLife together with Umeå University and the county of Västerbotten to develop biological treatments for periodontitis and peri-implantitis
Omnio together with Umeå university and the county council selected by the Vinnova program SweLife receive support of a total of SEK 3 million to develop new treatments for periodontitis and peri-implantitis. In competition with 120 applications, 16 were selected that were considered to have the greatest potential to lead to future better health. Omnio's project was one of these.